Zimmer introduces the first low volume single-injection hyaluronate (HA) viscosupplement injectable: Gel-One® Cross-linked Hyaluronate. Gel-One Hyaluronate delivers a safe and effective treatment protocol for patients with knee pain associated with osteoarthritis (OA). Through a randomized clinical trial, there were no reports of pseudosepsis (severe acute inflammatory responses).
With Gel-One Hyaluronate, the proven relief of sodium hyaluronate (hyaluronan) is available in a small dose – only 3mL – providing a complete treatment regime with one injection. The 3mL volume is half that of the other single injection product on the market, and a lower aggregate volume than the other three-, four-, and five-injection HA treatments.
This website is intended only for US residents.
Gel-One® is a registered trademark of Seikagaku Corporation.